Effect of hormone replacement therapy on inflammation‐sensitive proteins in post‐menopausal women with Type 2 diabetes

Manning, Patrick J.; Sutherland, W. H. F.; Allum, Anne R.; Jong, Sylvia A. de; Jones, Stephanie

doi:10.1046/j.1464-5491.2002.00808.x

Cited by 27 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether this represents a fundamental biological process between sexes or more probably is a reflection of a different pattern of confounding between men and women is uncertain. In an attempt to examine the latter, we investigated whether hormone replacement therapy (HRT) could be one such sex-linked confounding factor, since HRT is associated with increased CRP levels in women [39]. However, the positive CRP-diabetes association in women could not be explained by use of oestrogen or HRT.…”

Section: Discussionmentioning

confidence: 99%

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

et al. 2009

View full text Add to dashboard Cite

Aims/hypothesis We examined the association between serum C-reactive protein (CRP) and incident diabetes in a prospective study, and added these data to a literature-based meta-analysis to explore potential sources of heterogeneity between studies. Methods We analysed a case-control study nested within the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort, including 293 incident diabetes cases and 708 controls. We combined 16 published studies on CRP and incident diabetes in a random-effect meta-analysis. Results In the EPIC-Norfolk cohort, serum CRP was associated with a higher risk of diabetes after adjusting for age, sex, BMI, family history of diabetes, smoking and physical activity (OR 1.49, comparing the extreme thirds of CRP distribution [95% CI 1.03-2.15], p=0.03). However, the association was completely attenuated after further adjustment for WHR, serum γ-glutamyltransferase and serum adiponectin (OR 1.00; 95% CI 0.66-1.51, p=1.0). In a meta-analysis of 16 published studies with 3,920 incident diabetes cases and 24,914 controls, the RR was 1.72 (95% CI 1.54-1.92), comparing the extreme thirds of CRP distribution, with substantial heterogeneity between studies (I 2 =52.8%, p=0.007). Conclusions/interpretation Initial evidence of association between CRP and incident diabetes was confounded by central adiposity, markers of liver dysfunction and adiponectin in the primary analysis. Despite an overall positive association in the meta-analysis, considerable heterogeneity existed between studies. The degree of adjustment for central adiposity and baseline glycaemia explained some of this heterogeneity and suggests that CRP may not be an independent risk factor for type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…CRP has been shown to increase after HRT (Manning et al 2002), but CRP concentrations were not increased following supplementation in the ISOHEART study, and therefore isoflavones do not appear to mimic oestrogen action, at least as far as the effects on CRP are concerned. On the contrary, although the data for CRP was highly skewed and the statistical processing was problematic, thorough statistical analysis of the data by logistic regression has demonstrated that isoflavone consumption has a beneficial effect on CRP concentrations compared with the placebo treatment (see Hall et al 2005).…”

Section: Discussionmentioning

confidence: 98%

“…HRT has been suggested to decrease cell adhesion molecules (Koh et al 1997) and endothelin 1 (Wilcox et al 1997) concentrations. However, recent reports have shown adverse effects of HRT on the vasculature, including increased concentrations of CRP (Cushman et al 1999;Manning et al 2002) and increased risk of thrombosis (Nelson et al 2002). In addition to the latter, the reported association between hormonedependent cancers and HRT (Beral et al 2005), as well as unexpected reports of increased CVD rates with HRT (Grady et al 2002), has led to investigation of alternative therapies to counteract oestrogen deficiency at menopause.…”

Section: Cvd and Menopausementioning

confidence: 99%

“…Hormone-replacement therapy (HRT) has been widely used to counteract the adverse effects of oestrogen deficiency. However, the recently reported lack of HRT efficacy in relation to CVD progression (Nelson et al 2002) and evidence of adverse effects (Cushman et al 1999;Manning et al 2002) has led to increased interest in alternative therapies such as isoflavones. Isoflavones are phyto-oestrogens bearing a similar structure to mammalian oestrogen and, therefore, could act as oestrogen mimics or selective oestrogen-receptor (ER) modulators.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women

2006

View full text Add to dashboard Cite

The increase in CVD incidence following the menopause is associated with oestrogen loss. Dietary isoflavones are thought to be cardioprotective via their oestrogenic and oestrogen receptor-independent effects, but evidence to support this role is scarce. Individual variation in response to diet may be considerable and can obscure potential beneficial effects in a sample population; in particular, the response to isoflavone treatment may vary according to genotype and equol-production status. The effects of isoflavone supplementation (50 mg/d) on a range of established and novel biomarkers of CVD, including markers of lipid and glucose metabolism and inflammatory biomarkers, have been investigated in a placebo-controlled 2 · 8-week randomised cross-over study in 117 healthy post-menopausal women. Responsiveness to isoflavone supplementation according to (1) single nucleotide polymorphisms in a range of key CVD genes, including oestrogen receptor (ER) a and b and (2) equol-production status has been examined. Isoflavones supplementation was found to have no effect on markers of lipids and glucose metabolism. Isoflavones improve C-reactive protein concentrations but do not affect other plasma inflammatory markers.

show abstract

“…interleukina 6 (IL-6), pozostają niezmienione pod wpływem HTZ, zarówno w grupie kontrolnej, jak i u pacjentek chorych na cukrzycę [31,32].…”

Section: Hormonalna Terapia Zastępcza U Pacjentek Chorych Na Cukrzycęunclassified

Hormonalna terapia zastępcza a cukrzyca

Wender-Ożegowska¹,

Ożegowska²,

Gutaj³

2013

View full text Add to dashboard Cite

StreszczenieCelem pracy jest przedstawienie poglądów i stanu wiedzy na temat hormonalnej terapii zastępczej (HTZ) u kobiet chorych na cukrzycę.Aktualny stan wiedzy dowodzi, że cukrzyca nie stanowi przeciwwskazania do stosowania HTZ. Dostępne badania wykazały brak jej negatywnego wpływu na kontrolę glikemii, a wręcz wskazują nie tylko na jej korzystny wpływ na gospodarkę węglowodanową, lecz również większości preparatów na profil lipidowy pacjentek. Najkorzystniejszy efekt metaboliczny wydaje się mieć terapia transdermalna z zastosowaniem naturalnego progesteronu lub noretysteronu.Stosowanie HTZ nie wpływa prawdopodobnie korzystnie na profilaktykę jak i leczenie choroby wieńcowej i należy o tym informować pacjentki przed rozpoczęciem terapii.Nie zwalnia to jednak lekarzy z przepisywania tej formy terapii w przypadku stwierdzenia u pacjentki chorej na cukrzycę objawów menopauzalnych bądź ryzyka osteoporozy, bowiem potencjalne negatywne skutki jak i korzyści tej formy terapii są zbliżone do efektów uzyskanych w grupach zdrowych pacjentek. Należy jednak, jak zawsze przy wyborze metody leczenia, zastosować najbezpieczniejszą dla danej pacjentki formę terapii.Słowa kluczowe: hormonalna terapia zastępcza, cukrzyca. SummaryThe purpose of the study is to present today's opinions on hormonal replacement therapy among women with diabetes.Actual knowledge demonstrates that there are no contraindications for HRT in diabetes. This therapy has no adverse effect on glycemic metabolism in diabetic women and selected preparations have a positive effect. Some forms improve the lipid profile in this population. It seems that transdermal therapy containing 17-beta estradiol and natural progesterone or NETA may be the preferable method of treatment recommended for diabetic patients.Nowadays, the use of HRT for the prevention or treatment of CVD is unclear and women should be informed about these data before starting the therapy. This should not stop doctors from prescribing HRT to diabetic women mainly for menopausal symptoms and for the prevention of osteoporosis.On the basis of the data collected so far, however, it is suggested that the risk-benefit ratio is similar to that for the nondiabetic population. A decision whether to prescribe HRT should always be tailored to the individual. Individual assessment of the potential benefits and risks of HRT treatment should be performed for women with diabetes as it is for all women when HRT is considered.

show abstract

Effect of hormone replacement therapy on inflammation‐sensitive proteins in post‐menopausal women with Type 2 diabetes

Cited by 27 publications

References 31 publications

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women

Hormonalna terapia zastępcza a cukrzyca

Contact Info

Product

Resources

About